18.1 C
New York
Wednesday, June 3, 2026

Tag: infants

newssourceFORcompanyinformationcontent1marketreleases

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with...

Châtillon, France, June 2, 2026

/C O R R E C T I O N — Nestle USA/

In the news release, A WINNING SMILE AND THE UNSUNG HEROES BEHIND IT: GERBER® CELEBRATES BABY CAMERON AND HIS PARENTS FOR 2026 PHOTO SEARCH,...

InventHelp Inventor Develops New Potty Training Accessory (SGM-538)

PITTSBURGH, Aug. 15, 2025 /PRNewswire/ -- "I wanted to create a product that would make potty training a less stressful and more positive experience...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

BrightPath Early Learning and Child Care Celebrates 15 Years of Giving Children the Best Start in Life

Leading Child Care Provider Marks Milestone with a Chance to Win a Full Year of Free Child Care WEST SENECA, N.Y., Aug. 8, 2025 /PRNewswire/...

Thyseed Newborn Baby Bottle with Bottom Vent Design: Clinically Proven to Reduce Colic and Spit-up by 30%

New anti-colic system delivers clinically tested relief for newborn digestive discomfort BEIJING, Aug. 6, 2025 /PRNewswire/ -- Thyseed, an established name in global infant care,...

Thyseed Newborn Baby Bottle with Bottom Vent Design: Clinically Proven to Reduce Colic and Spit-up by 30%

New anti-colic system delivers clinically tested relief for newborn digestive discomfort BEIJING, Aug. 6, 2025 /PRNewswire/ -- Thyseed, an established name in global infant care,...

Thyseed Is Set to Support Southeast Asian Families with Safer Infant Feeding Solutions, Powered by Medical-Grade Technology

BEIJING, Aug. 6, 2025 /PRNewswire/ -- Thyseed, an established name in global infant care, recently announced plans to introduce its premium, safety-certified feeding solutions to...

Media advisory: Shriners Hospitals for Children Canada Invites Media to its Annual Golf Tournament

MONTREAL, Aug. 04, 2025 (GLOBE NEWSWIRE) --

About Shriners Hospitals for Children Canada
Established in Montreal in 1925, Shriners Hospitals for Children Canada is a bilingual, short-term, acute care hospital, providing ultra-specialized orthopaedic care to children from across Canada and around the world. The mission of the hospital is to provide treatment and rehabilitation to infants, children and young adults with orthopaedic and neuromuscular problems such as scoliosis, osteogenesis imperfecta (brittle bone disease), clubfeet, hip dysplasia, leg length discrepancies and cerebral palsy, among others. The hospital is committed to excellence and innovation in clinical practice, research and education. Affiliated with McGill University, the hospital provides clinical experience and teaching for residents and allied professionals within its outstanding new facility on the Glen site. The hospital is present in communities across Canada, thanks to telemedicine, outreach clinics and satellite clinics.

RBGLY DEADLINE TOMORROW: ROSEN, A TOP RANKED LAW FIRM, Encourages Reckitt Benckiser Group PLC Investors to Secure Counsel Before Important August 4 Deadline in...

NEW YORK, Aug. 03, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares (“ADSs”) of Reckitt Benckiser Group PLC (OTC: RBGLY) between January 13, 2021 and July 28, 2024, both dates inclusive (the “Class Period”), of the important August 4, 2025 lead plaintiff deadline.

RECKITT (RBGLY) URGENT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Reckitt Benckiser Group plc...

Bragar Eagel & Squire, P.C. Litigation Attorney Brandon Walker Encourages Investors Who Suffered Losses In Reckitt (RBGLY) To Contact Him Directly To Discuss Their Options

IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 second quarter financial results before the market opens on Friday, August 1, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. The ETF stated that “targeting LP.8.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”2

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInfants

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers